Home/Pipeline/LYN-005 (Nortiva)

LYN-005 (Nortiva)

Schizophrenia

Phase 3Active

Key Facts

Indication

Schizophrenia

Phase

Phase 3

Status

Active

Company

Lyndra

About Lyndra

Lyndra Therapeutics is developing a disruptive oral drug delivery platform that aims to radically improve medication adherence and patient outcomes by converting daily pills into weekly or monthly doses. Founded in 2015 and based in Watertown, Massachusetts, the company's core technology is a gastric-retentive dosage form that slowly releases medication in the stomach over an extended period. With a lead program in schizophrenia and a pipeline targeting chronic diseases, Lyndra is positioned to address a significant unmet need in long-term pharmacotherapy. The company is privately held and has secured substantial funding from prominent healthcare investors.

View full company profile

Therapeutic Areas

Schizophrenia HIV Prevention Opioid Use Disorder Chronic Disease

Other Schizophrenia Drugs

Drug	Company	Phase	Status
DB103 (Pomaglumetad)	Denovo Biopharma	Phase 2b/3	Active
ZZ6398	Zhongze Therapeutics	Phase 1/2	Active
RBP-7000 (PERSERIS®)	Indivior	Marketed	Commercial
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
Schizophrenia Candidate	Teva	Phase 3	Active
Schizophrenia Model Service	NeuroProof	Pre-clinical	Active
TerXT	Terran Biosciences	Late-stage (Pre-Phase 3)	Active
Undisclosed Program	Curemark	Preclinical	Active
Schizophrenia Intermediate	OFD Biopharma	Proof of concept	Active
Schizophrenia	Keltic Pharma Therapeutics	Pre-clinical	Active
AVAT-031	Avata Biosciences	Discovery	Active
Risperidone Implant	Delpor	Phase 1b/2a / Late-stage	Active